Business
Bio-Thera Solutions' Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi® and Simponi Aria®; Accord BioPharma to Commercialize IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) in the United States
Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Accord BioPharma, Inc, the U.S. specialty division of Intas Pharmaceuticals, Ltd. ("Intas"), focused on the development of oncology, immunology and central nervous system (CNS) therapies, today announced Accord BioPharma received marketing authorization in the United States of America for IMMGOLIS (formerly known as BAT2506), a SIMPONI® (golimumab) bios
About this update from Bio-thera Solutions, Ltd. Class A
[{"type":"text","content":"GUANGZHOU, China, May 18, 2026 /PRNewswire/ -- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Accord BioPharma, Inc, the U.S. specialty division of Intas Pharmaceuticals, Ltd. ("Intas"), focused on the development of oncology, immunology and central nervous system (CNS) therapies, today announced Accord BioPharma received marketing authorization in the United States of America for IMMGOLIS (formerly known as BAT2506), a SIMPONI® (golimumab) biosimilar, for the treatment of adults patients with moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate, and for the treatment of adult patients with moderately to severely active ulcerative colitis (UC). The FDA also approved IMMGOLIS INTRI (golimumab-sldi), a biosimilar to Simponi Aria® (golimumab), for the treatment of adult patients with moderately to severely active RA in combination with methotrexate. IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) are the first FDA approved biosimilars to Simponi® (golimumab) and Simponi Aria® (golimumab) for rheumatoid arthritis in combination with methotrexate and for ulcerative colitis.","length":1255,"tagName":"p"},{"type":"image","alt":"Bio-Thera Solutions Announces Exclusive Commercialization and License Agreement with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (golimumab), in the United States of America (PRNewsfoto/Bio-Thera Solutions, Ltd)","displaySize":"","headline":null,"caption":"Bio-Thera Solutions Announces Exclusive Commercialization and License Agreement with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (golimumab), in the United States of America (PRNewsfoto/Bio-Thera Solutions, Ltd)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":164,"url":"https://media.zenfs.com/en/prnewswire.com/9ba3417a034ec44b6148845f431884f4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qTgeC.CM1hCASG.1efQpLA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI4OQ--/https://media.zenfs.com/en/prnewswire.com/9ba3417a034ec44b6148845f431884f4","width":400,"height":164},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/UWxKf_6SLOJN.c5TFu5TLw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTI2Mg--/https:...